Premium
Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type‐16 (HPV‐16) in sera from patients with cervical intraepithelial neoplasia and children
Author(s) -
Cason John,
Kambo Parminder K.,
Best Jennifer M.,
McCance Dennis J.
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910500304
Subject(s) - cervical intraepithelial neoplasia , epitope , antibody , medicine , virology , recombinant dna , hpv infection , cervical cancer , papillomaviridae , immunology , biology , cancer , gene , genetics
Abstract Antibodies to the major (L1) coat protein of human papilloma‐ virus type 16 (HPV‐16) in sera from patients with cervical intra‐epithelial neoplasia (CIN) have been investigated by means of recombinant proteins and synthetic peptides. When L1‐ HPV‐16 fusion proteins were used in immunoblot assays, no antibody reactivity was found in sera from 52 patients with CIN or from 21 unrelated children. Amino‐acid sequence analyses indicated that L1‐HPV‐16 amino acids 473 to 492 may contain an HPV‐16 type‐restricted epitope since the greatest diversity occurs in this region. In the ELISA, seropositivity to peptides 473 to 492 was more common among CIN patients whose biopsies contained HPV‐16 DNA (91%, 21 of 23) than among their children (24%, 5 of 21; p < 0.001) or other CIN patients with HPV‐16 DNA‐negative biopsies (66%, 19 of 29; p < 0.05), but was unrelated to the severity of the CIN lesion. Antibodies to L1‐HPV‐16 peptide 473 to 492 among seropositive CIN patients cross‐reacted with the analagous L1‐HPV‐33, but not with the L1‐HPV‐6b peptide, and were predominantly IgM. In contrast, antibodies which recognized a less variable region of L1 ‐HPV‐16 (amino acids 279 to 293) showed no association with HPV‐16 DNA status. Seropositivity to the L1‐HPV‐6b (amino acids 473–492) was less frequent (33%) among CIN patients and unassociated with HPV‐16 DNA status ( p > 0.1); however 51% (37 of 72) of patients with genital warts had antibodies to this peptide.